Lessons learned from lung cancer genomics: The emerging concept of individualized diagnostics and treatment

Journal of Clinical Oncology

Volumn 31, Issue 15, 2013, Pages 1858-1865

  Buettner, Reinhard ^a   Wolf, Jürgen ^a   Thomas, Roman K ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER DIAGNOSIS; CANCER GENETICS; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; GENOMICS; HUMAN; LUNG CANCER; MOLECULAR DIAGNOSTICS; NONHUMAN; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATIONAL EMOTIVE BEHAVIOR THERAPY; REVIEW; TAXONOMY; TUMOR CLASSIFICATION; ADENOCARCINOMA; GENETICS; LUNG TUMOR; METHODOLOGY; MOLECULAR MEDICINE; MUTATION; ONCOLOGY; TRANSLATIONAL RESEARCH;

ADENOCARCINOMA; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MEDICAL ONCOLOGY; MOLECULAR MEDICINE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSLATIONAL MEDICAL RESEARCH;

MLCS; MLOWN;

EID: 84880449591     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.9867     Document Type: Review

References (89)

1. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
2. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
3. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
4. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 363:1693-1703, 2010
5. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
6. Engelman JA, Chen L, Tan X, et al: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356, 2008
7. Sos ML, Fischer S, Ullrich R, et al: Identifying genotype-dependent efficacy of single and combined PI3K-And MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 106:18351-18356, 2009
8. Ju YS, Lee WC, Shin JY, et al: A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22:436-445, 2012
9. Takeuchi K, Soda M, Togashi Y, et al: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381, 2012
10. Lipson D, Capelletti M, Yelensky R, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384, 2012
11. Kohno T, Ichikawa H, Totoki Y, et al: KIF5BRET fusions in lung adenocarcinoma. Nat Med 18: 375-377, 2012
12. Weiss J, Sos ML, Seidel D, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93, 2010
13. Dutt A, Ramos AH, Hammerman PS, et al: Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6:e20351, 2011
14. Hammerman PS, Sos ML, Ramos AH, et al: Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1:78-89, 2011
15. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
16. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
17. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
18. Pao W, Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760-774, 2010
19. Benson JD, Chen YN, Cornell-Kennon SA, et al: Validating cancer drug targets. Nature 441:451-456, 2006
20. Sellers WR: A blueprint for advancing genetics-based cancer therapy. Cell 147:26-31, 2011
21. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
22. Klüter S, Simard JR, Rode HB, et al: Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: A tool for dissecting kinase drug resistance. Chembiochem 11: 2557-2566, 2010
23. Michalczyk A, Klüter S, Rode HB, et al: Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. Bioorg Med Chem 16:3482-3488, 2008
24. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
25. Kwak EL, Sordella R, Bell DW, et al: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102:7665-7670, 2005
26. Zhou W, Ercan D, Chen L, et al: Novel mutantselective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070-1074, 2009
27. Li D, Ambrogio L, Shimamura T, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711, 2008
28. Sos ML, Rode HB, Heynck S, et al: Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 70:868-874, 2010
29. Xu L, Kikuchi E, Xu C, et al: Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 72:3302-3311, 2012
30. Regales L, Gong Y, Shen R, et al: Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119:3000-3010, 2009
31. Janjigian YY, Groen HJ, Horn L, et al: Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 29:482s, 2011 (suppl; abstr 7525)
32. Jänne PA, Boss DS, Camidge DR, et al: Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 17:1131-1139, 2011
33. Miller VA, Hirsh V, Cadranel J, et al: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 13:528-538, 2012
34. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075, 2008
35. Rodenhuis S, Slebos RJ, Boot AJ, et al: Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 48:5738-5741, 1988
36. Barbie DA, Tamayo P, Boehm JS, et al: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112, 2009
37. Scholl C, Fröhling S, Dunn IF, et al: Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834, 2009
38. Kumar MS, Hancock DC, Molina-Arcas M, et al: The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149:642-655, 2012
39. Luo J, Emanuele MJ, Li D, et al: A genomewide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848, 2009
40. Tolcher A, Baird R, Patnaik A, et al: A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol 29:195s, 2011 (suppl; abstr 3004)
41. Jiang H, Reinhardt HC, Bartkova J, et al: The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23: 1895-1909, 2009
42. Solit DB, Garraway LA, Pratilas CA, et al: BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362, 2006
43. Sos ML, Michel K, Zander T, et al: Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119:1727-1740, 2009
44. Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607, 2012
45. Garnett MJ, Edelman EJ, Heidorn SJ, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575, 2012
46. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-20937, 2007
47. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007
48. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26, 2011
49. Ohashi K, Sequist LV, Arcila ME, et al: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109:E2127-E2133, 2012
50. Zakowski MF, Ladanyi M, Kris MG, et al: EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355:213-215, 2006
51. Yun CH, Mengwasser KE, Toms AV, et al: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105:2070-2075, 2008
52. Chmielecki J, Foo J, Oxnard GR, et al: Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3:90ra59, 2011
53. Wong AJ, Ruppert JM, Bigner SH, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992
54. Yap TA, Vidal L, Adam J, et al: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol
55. Heuckmann JM, Rauh D, Thomas RK: Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol 30:3417-3420, 2012
56. Walter AO, Tjin R, Haringsma H, et al: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations. AACR-NCIEORTC International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, November 12-16, 2011
57. Engelman JA, Jänne PA, Mermel C, et al: ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 102:3788-3793, 2005
58. Faber AC, Li D, Song Y, et al: Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 106:19503-19508, 2009
59. Engelman JA, Mukohara T, Zejnullahu K, et al: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-Amplified lung cancer. J Clin Invest 116:2695-2706, 2006
60. Sos ML, Koker M, Weir BA, et al: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69:3256-3261, 2009
61. Sasaki T, Okuda K, Zheng W, et al: The neuroblastoma-Associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-Translocated cancers. Cancer Res 70:10038-10043, 2010
62. Heuckmann JM, Hölzel M, Sos ML, et al: ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 17: 7394-7401, 2011
63. Heukamp LC, Thor T, Schramm A, et al: Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med 4:141ra91, 2012
64. Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-525, 2012
65. Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244-285, 2011
66. Miller VA, Riely GJ, Zakowski MF, et al: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26:1472-1478, 2008
67. Motoi N, Szoke J, Riely GJ, et al: Lung adenocarcinoma: Modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32:810-827, 2008
68. Corcoran RB, Ebi H, Turke AB, et al: EGFRmediated re-Activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discovery 2:227-235, 2012
69. Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103, 2012
70. Meyerson M, Gabriel S, Getz G: Advances in understanding cancer genomes through secondgeneration sequencing. Nat Rev Genet 11:685-696, 2010
71. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-Terminating inhibitors. Proc Natl Acad Sci U S A 74:5463-5467, 1977
72. Thomas RK, Nickerson E, Simons JF, et al: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12:852-855, 2006
73. Querings S, Altmüller J, Ansén S, et al: Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 6:e19601, 2011
74. Gnirke A, Melnikov A, Maguire J, et al: Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 27:182-189, 2009
75. Thomas RK, Baker AC, Debiasi RM, et al: High-Throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-351, 2007
76. Newton CR, Graham A, Heptinstall LE, et al: Analysis of any point mutation in DNA: The amplification refractory mutation system (ARMS). Nucleic Acids Res 17:2503-2516, 1989
77. Chmielecki J, Peifer M, Jia P, et al: Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res 38:6985-6996, 2010
78. Wagle N, Berger MF, Davis MJ, et al: Highthroughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov 2:82-93, 2012
79. Peifer M, Fernández-Cuesta L, Sos ML, et al: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44:1104-1110, 2012
80. Imielinski M, Berger AH, Hammerman PS, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107-1120, 2012
81. Gan HK, You B, Pond GR, et al: Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst 104:590-598, 2012
82. Shaw AT, Camidge DR, Engelman JA, et al: Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 30:482s, 2012 (suppl; abstr 7508)
83. Lin Y, Shih WJ: Adaptive two-stage designs for single-Arm phase IIA cancer clinical trials. Biometrics 60:482-490, 2004
84. Fabian MA, Biggs WH 3rd, Treiber DK, et al: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336, 2005
85. Ullrich RT, Zander T, Neumaier B, et al: Early detection of erlotinib treatment response in NSCLC by 3-deoxy-3-[F]-fluoro-L-Thymidine ([F]FLT) positron emission tomography (PET). PLoS One 3:e3908, 2008
86. Nogová L, Boellaard R, Kobe C, et al: Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med 50:1815-1819, 2009
87. Zander T, Scheffler M, Nogova L, et al: Early prediction of nonprogression in advanced non-smallcell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 29:1701-1708, 2011
88. Kris MG, Johnson BE, Kwiatkowski DJ, et al: Identification of driver mutations in tumor specimens from 1, 000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29:477s, 2011 (suppl; abstr CRA7506)
89. Zander T, Heukamp LC, Bos MCA, et al: Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment. J Clin Oncol 30:663s, 2012 (suppl; abstr CRA10529)